The present invention relates generally to stent grafts for use in body vessels to treat medical conditions. In particular, this invention relates to a flared asymmetric stent having opposing sets of curved apices, where the curved section of one set of apices has a radius of curvature that is greater than the curved section of the other set of apices, and may present a lower profile, better compliance with irregular vascular geometry, and higher sealing forces than conventional stents.
Stents may be inserted into an anatomical vessel or duct for various purposes. Stents may maintain or restore patency in a formerly blocked or constricted passageway, for example, following a balloon angioplasty procedure. Other stents may be used for different procedures, for example, stents placed in or about a graft have been used to hold the graft in an open configuration to treat an aneurysm. Additionally, stents coupled to one or both ends of a graft may extend proximally or distally away from the graft to engage a healthy portion of a vessel wall away from a diseased portion of an aneurysm to provide endovascular graft fixation.
Stents may be either self-expanding or balloon-expandable, or they can have characteristics of both types of stents. Various existing self-expanding and balloon-expandable stent designs and configurations comprise generally symmetrical end regions including one or more apices formed of nitinol or another alloy wire formed into a ring. The apices commonly comprise relatively acute bends or present somewhat pointed surfaces, which may facilitate compression of the stent to a relatively small delivery profile due to the tight bend of the apices. Although having this advantage, in some situations, such relatively acute or pointed apices may be undesirable, in particular in vessel anatomies that are curved or tortuous such as, for example, the thoracic aorta.
The thoracic aorta presents a challenging anatomy for stent grafts used to treat thoracic aneurysms or dissections. The thoracic aorta comprises a curve known as the aortic arch, which extends between the ascending thoracic aorta (closet to the heart) and the descending thoracic aorta (which extends toward the abdominal aorta). Thoracic stent grafts are used to exclude thoracic aortic aneurysms. A stent graft's ability to conform to the tortuous anatomy of the aortic arch is a major concern. Current designs sometimes lack the desired sealing ability at the proximal end of the stent graft (closest to the heart). Also, current thoracic devices present a relatively large profile which, with some patients' anatomies may be problematic. Finally, many current stents have relatively acute points that may prevent them from being used in the aortic arch for fear of undesirable interaction with the artery wall after an extended amount of time in the patient.
Therefore, a generally nonsymmetrical stent having at least one relatively rounded apex that is less invasive in an expanded state than stents with more acute apices may alleviate the above problems, while providing an improved compliance to the aortic arch and increased radial force if used as a sealing and/or alignment stent, as well as a desirable ability to be crimped to a readily introducible diameter.
As one particular example, type-A thoracic aortic dissection (TAD-A) is a condition in which the intimal layer of the ascending thoracic aorta develops a tear, allowing blood to flow into the layers of the aortic wall, causing the development of a medial or subintimal hematoma. TAD-A is associated with a strikingly high mortality rate (about one-fourth to one-half of victims die within the first 24-48 hours). The current treatment for TAD-A is open surgery, where the chest is opened, the aorta is clamped, and a vascular prosthesis is sewn in place. Operative mortality rate for this procedure may be around 10%. Endovascular treatment of TAD-B (which affects the descending thoracic aorta) has been effective in reducing short-term and longer term mortality. Treatment of TAD-A may offer benefits as well, but is challenged by the likelihood that a graft or stent graft in the ascending aorta may migrate proximally toward the heart or distally away from it due to the turbulence of blood flow and the motion associated with the heart beating, thereby blocking coronary or great arteries, respectively. Therefore, it is desirable to provide an endovascular device configured to address the anatomic challenges of the ascending thoracic aorta including preventing migration of the device.
The present invention relates generally to stents for use in body vessels to treat medical conditions. In particular, this invention relates to a stent having opposing sets of curved apices, where the curved section of one set of apices has a radius of curvature that is greater than the curved section of the other set of apices, and may present a lower profile than conventional stents. This configuration presents an asymmetrical stent with a graft having one or more intermediate stents that may be symmetrical or asymmetrical and forming columnar support in a stent graft configured for treatment of a thoracic ascending aortic dissection. Specifically, embodiments of the presently-presented stent may maintain a low profile while improving compliance with highly tortuous anatomy (such as, for example, that found in the region of the thoracic aorta and particularly the aortic arch) while providing improved radial sealing force compared to some current devices. In another aspect, the presently-presented stent may provide support and spacing within the larger context of a stent or stent-graft device that will allow, for example, placement of ancillary stents and/or stent-grafts.
In one example, the present invention may include a stent that includes at least one proximal apex and at least one distal apex connected with the proximal apices by a plurality of generally straight portions; where each proximal apex includes a first curved portion and each distal apex comprises a second curved portion; where the first curved portion and the second curved portion each includes at least one radius of curvature, and the radius of curvature of at least one of the proximal apices is greater than the radius of curvature of at least one of the distal apices.
In another example, the present invention may include at least one wire formed into stent including a ring of alternating opposed, generally curved apices where a radius of curvature of a plurality of the apices in a first direction is greater than a radius of curvature of the apices in an opposite direction. In still another example a stent graft may include a bare alignment stent at each end, each of the alignment stents comprising an asymmetrical geometry with broadly-rounded or filleted bare apices such that the stent graft is configured and dimensioned for treatment of a thoracic ascending aorta dissection.
Advantageously, the rounded apices may provide atraumatic contact with a vessel, while the combination of more rounded and less rounded apices provides for a low-profile stent that includes desirable compressibility during introduction and desirable compliance and sealing profiles when deployed in a vessel.
The invention can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the invention. Moreover, in the figures, like referenced numerals designate corresponding parts throughout the different views.
The present invention relates generally to stents for use in body vessels to treat medical conditions. In particular, this invention relates to a novel asymmetric stent having opposing sets of curved apices, where the curved section of one set of apices has a radius of curvature that is greater than the curved section of the other set of apices, and may present a lower profile than conventional stents. The lower profile may present advantages for use in patients with particularly tortuous or small-diameter vessels.
In the present application, the term “proximal” refers to a direction that is generally closest to the heart during a medical procedure, while the term “distal” refers to a direction that is furthest from the heart during a medical procedure. Reference throughout is made to proximal and distal apices, but those of skill in the art will appreciate that the proximal-distal orientation of stents of the present invention may be reversed without exceeding the scope of the claims.
As shown in
The asymmetric stent may be configured such that, when used with a graft, it will provide a sufficiently strong radial force at the graft's end openings to hold the graft material open against the artery wall. Also, the stent is intended to be short in length so that the graft will include flexibility sufficient to accommodate a patient's anatomy. This combination of flexibility and strong radial force provides an improved seal between the graft and artery wall. In addition, enhanced flexibility is provided as well, particularly when one or more stents are used to provide short segments and better accommodate curves.
In these and other examples, the ratio of the proximal apices' radius of curvature to the distal apices' radius of curvature may be about 2.6:1 to about 18:1, and desirably may be about 6:1. The outer circumference of the stent 200 preferably is generally consistent such that, in this configuration, a solid outer face around the stent 200 would form a cylinder, although the stent will most preferably provide compliance with a surface less smooth than a cylinder.
The rounded points on the stent may protrude from the graft material only a small amount as is shown in
As shown in the end view of
In another embodiment, shown in
The graft material 810 preferably is secured to one or more stents 812 along its length that may be symmetrical (e.g., z-type) stents or asymmetrical stents of a type discussed above and that are configured to provide columnar support and maintain an open lumen therethrough. The distance between the apices 806 and a proximal end of the graft material 810 most preferably is such that it will provide an open path for coronary blood flow. Specifically, it is preferable that a height H between the apices 806 and the proximal edge of the graft material 810 is equal to or less than a distance from an aortic root surface that is between a patient's aortic valve and a distal-most opening of that patient's coronary arteries immediately adjacent the aortic valve, as is explained below in greater detail. This height is easily controlled by specific determination of where the stent 802 is secured to the graft material 810.
The height H for a specific patient's stent graft may be customized based upon echogenic and/or radiologic measurement of the dimensions of the patient's ascending aorta and its lumen. The expanded outermost diameter of the proximal and distal stents may be about 16 mm to about 57 mm. The outermost diameter of the graft body 810 may be about 16 mm to about 54 mm. And, the length of the entire device may be from about 8 cm to about 25 cm. Preferably, the length and outer diameters of the device 800 are configured and dimensioned to treat a dissection of the ascending thoracic aorta without proximal or distal migration, with particular configuration of the proximal stent 802 to engage the aorta at or distal of the aortic root. Preferably, the stents are NiTi stents and the graft fabric is a low-profile graft fabric, such that the device may collapse to about 16 Fr to about 18 Fr for introduction, which presents an added advantage over current devices, which typically collapse only to about 20 Fr or greater. The curvatures and proportions of the bare and/or intermediate stents may be the same as described for any of the embodiments shown in the other figures and/or discussed above herein.
It should be appreciated that the stent graft 800 presents several advantages compared to the open-heart graft surgeries now used to treat TAD-A. The stent graft 800 can be placed using a minimally invasive procedure (e.g., Seldinger technique) rather than subjecting the patient to the risks and surgical trauma associated with open heart surgery. It will provide a patent path of fluid communication that preferably will isolate the dissection to decrease risk of it rupturing while not occluding the coronary or other arteries branching off from the aorta. It should be appreciated that, provided the inclusion of the flared configuration, virtually all of the characteristics of the other stent embodiments described above may be included in the stents 802, 804 of the stent graft 800, including differently proportioned, filleted, or other apical configurations. It should also be appreciated that a stent graft configuration as shown in
A clear but surprising advantage of the present design over prior stent graft designs has been discovered, as used within a curvature similar to the ascending thoracic aorta. A clear tube 905 simulating the curvature of an ascending thoracic aorta was provided, as shown in
However, the surprising advantage conferred by the present design arose from use of a stent graft (e.g., stent graft 800 of the type claimed herein). The enhanced flexibility of the presently-claimed design provides a superior conformance that provides an average PNG of 0.89 mm, which is significantly lower than the prior art devices that were tested.
Stent examples of the present invention may be constructed of NiTi alloys or other materials presently known or yet to be developed, all within the scope of the present invention. The stents preferably are made from Nitinol wire and will therefore be MRI compatible. In another preferable embodiment, a stent may be made from a laser-cut Nitinol cannula, effectively rendering it a seamless or nearly-seamless wire-like construction. Nitinol's superelastic properties will facilitate the stents ability to be crimped down into a low profile delivery system.
Although various examples of the invention have been described, the invention is not to be restricted except in light of the attached claims and their equivalents. Moreover, the advantages described herein are not necessarily the only advantages of the invention and it is not necessarily expected that every example of the invention will achieve all of the advantages described. Different embodiments not expressly described herein including those with features combined in a different manner than expressly illustrated herein may be practiced within the scope of the present invention. For at least these reasons, this narrative description should not be construed as defining the invention; rather, the claims set forth and define the present invention.
This application is a continuation-in-part of pending U.S. application Ser. No. 12/332,904, filed Dec. 11, 2008, which claims priority to U.S. Prov. App. Ser. No. 61/016,753, filed Dec. 26, 2007, each of which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
5258021 | Duran | Nov 1993 | A |
5292331 | Boneau | Mar 1994 | A |
5403341 | Solar | Apr 1995 | A |
5569295 | Lam | Oct 1996 | A |
5607468 | Rogers et al. | Mar 1997 | A |
5630829 | Lauterjung | May 1997 | A |
5674278 | Boneau | Oct 1997 | A |
5843164 | Frantzen et al. | Dec 1998 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5906639 | Rudnick et al. | May 1999 | A |
5913897 | Corso et al. | Jun 1999 | A |
5961546 | Robinson et al. | Oct 1999 | A |
5993482 | Chuter | Nov 1999 | A |
6071307 | Rhee et al. | Jun 2000 | A |
6203569 | Wijay | Mar 2001 | B1 |
6293966 | Frantzen | Sep 2001 | B1 |
6296662 | Caffey | Oct 2001 | B1 |
6348068 | Campbell et al. | Feb 2002 | B1 |
6368345 | Dehdashtian et al. | Apr 2002 | B1 |
6423090 | Hancock | Jul 2002 | B1 |
6451051 | Drasler et al. | Sep 2002 | B2 |
6539984 | Lam | Apr 2003 | B2 |
6582458 | White et al. | Jun 2003 | B1 |
6585757 | Callol | Jul 2003 | B1 |
6616689 | Ainsworth et al. | Sep 2003 | B1 |
6629994 | Gomez et al. | Oct 2003 | B2 |
6635083 | Cheng et al. | Oct 2003 | B1 |
6645242 | Quinn | Nov 2003 | B1 |
6648911 | Sirhan et al. | Nov 2003 | B1 |
6663661 | Boneau | Dec 2003 | B2 |
6673102 | Vonesh et al. | Jan 2004 | B1 |
6849088 | Dehdashtian et al. | Feb 2005 | B2 |
6962604 | Hijlkema | Nov 2005 | B2 |
7186263 | Golds et al. | Mar 2007 | B2 |
7331992 | Randall et al. | Feb 2008 | B2 |
7341598 | Davidson et al. | Mar 2008 | B2 |
7407509 | Greenberg et al. | Aug 2008 | B2 |
7473275 | Marquez | Jan 2009 | B2 |
7615072 | Rust et al. | Nov 2009 | B2 |
7758626 | Kim et al. | Jul 2010 | B2 |
7766962 | Quinn | Aug 2010 | B1 |
7794492 | Ishimaru et al. | Sep 2010 | B2 |
7887580 | Randall et al. | Feb 2011 | B2 |
8128678 | Leewood et al. | Mar 2012 | B2 |
8333799 | Bales et al. | Dec 2012 | B2 |
8348994 | Leopold et al. | Jan 2013 | B2 |
8425586 | Leopold et al. | Apr 2013 | B2 |
20020016627 | Golds | Feb 2002 | A1 |
20020022877 | Mueller et al. | Feb 2002 | A1 |
20030033003 | Harrison et al. | Feb 2003 | A1 |
20030088305 | Van Schie et al. | May 2003 | A1 |
20030125797 | Chobotov et al. | Jul 2003 | A1 |
20030130720 | DePalma et al. | Jul 2003 | A1 |
20030199967 | Hartley et al. | Oct 2003 | A1 |
20040054396 | Hartley et al. | Mar 2004 | A1 |
20040117003 | Ouriel et al. | Jun 2004 | A1 |
20040117004 | Osborne et al. | Jun 2004 | A1 |
20040215316 | Smalling | Oct 2004 | A1 |
20040215319 | Berra et al. | Oct 2004 | A1 |
20040254625 | Stephens et al. | Dec 2004 | A1 |
20050033406 | Barnhart et al. | Feb 2005 | A1 |
20050049674 | Berra et al. | Mar 2005 | A1 |
20050113905 | Greenberg et al. | May 2005 | A1 |
20050131516 | Greenhalgh | Jun 2005 | A1 |
20050154446 | Phillips et al. | Jul 2005 | A1 |
20050159803 | Lad et al. | Jul 2005 | A1 |
20050222671 | Schaeffer et al. | Oct 2005 | A1 |
20050273155 | Bahler et al. | Dec 2005 | A1 |
20060004436 | Amarant et al. | Jan 2006 | A1 |
20060052860 | Gomez et al. | Mar 2006 | A1 |
20060100695 | Peacock et al. | May 2006 | A1 |
20060161243 | Fearnot et al. | Jul 2006 | A1 |
20060190075 | Jordan et al. | Aug 2006 | A1 |
20060247761 | Greenberg et al. | Nov 2006 | A1 |
20060267247 | Anukhin et al. | Nov 2006 | A1 |
20070027525 | Ben-Muvhar | Feb 2007 | A1 |
20070055345 | Arbefeuille | Mar 2007 | A1 |
20070055347 | Arbefeuille | Mar 2007 | A1 |
20070067016 | Jung | Mar 2007 | A1 |
20070073388 | Krolik et al. | Mar 2007 | A1 |
20070135889 | Moore et al. | Jun 2007 | A1 |
20070142894 | Moore et al. | Jun 2007 | A1 |
20070163668 | Arbefeuille et al. | Jul 2007 | A1 |
20070168019 | Amplatz et al. | Jul 2007 | A1 |
20070179592 | Schaeffer | Aug 2007 | A1 |
20070185560 | Roeder et al. | Aug 2007 | A1 |
20070191927 | Bowe et al. | Aug 2007 | A1 |
20070203566 | Arbefeuille et al. | Aug 2007 | A1 |
20070208256 | Marilla | Sep 2007 | A1 |
20070219620 | Eells et al. | Sep 2007 | A1 |
20070219624 | Brown et al. | Sep 2007 | A1 |
20070225797 | Krivoruhko | Sep 2007 | A1 |
20070233220 | Greenan | Oct 2007 | A1 |
20070244547 | Greenan | Oct 2007 | A1 |
20070250152 | Xiao et al. | Oct 2007 | A1 |
20070282433 | Limon et al. | Dec 2007 | A1 |
20080033527 | Nunez et al. | Feb 2008 | A1 |
20080086190 | Ta | Apr 2008 | A1 |
20080109066 | Quinn | May 2008 | A1 |
20080114441 | Rust et al. | May 2008 | A1 |
20080119943 | Armstrong et al. | May 2008 | A1 |
20080195191 | Luo et al. | Aug 2008 | A1 |
20080269866 | Hamer et al. | Oct 2008 | A1 |
20080281399 | Hartley et al. | Nov 2008 | A1 |
20080319534 | Birdsall et al. | Dec 2008 | A1 |
20090005856 | Pappas et al. | Jan 2009 | A1 |
20090043376 | Hamer et al. | Feb 2009 | A1 |
20090048663 | Greenberg | Feb 2009 | A1 |
20090105809 | Lee et al. | Apr 2009 | A1 |
20090149946 | Dixon | Jun 2009 | A1 |
20090171437 | Brocker et al. | Jul 2009 | A1 |
20090177270 | Agnew et al. | Jul 2009 | A1 |
20120029624 | Dierking et al. | Feb 2012 | A1 |
20120239136 | Bruzzi | Sep 2012 | A1 |
Entry |
---|
Office Action for U.S. Appl. No. 12/622,351 dated Oct. 6, 2010, 12 pgs. |
Response to Office Action for U.S. Appl. No. 12/622,351 filed Mar. 9, 2011, 15 pgs. |
Office Action for U.S. Appl. No. 12/332,904 dated Oct. 4, 2010, 10 pgs. |
Response to Office Action for U.S. Appl. No. 12/332,904 filed Mar. 4, 2011, 13 pgs. |
Office Action dated Nov. 18, 2011 for U.S. Appl. No. 12/332,904, 15 pgs. |
Interview Summary dated Jan. 24, 2012 for U.S. Appl. No. 12/332,904, 2 pgs. |
Response to Office Action dated Feb. 21, 2012 for U.S. Appl. No. 12/332,904, 9 pgs. |
Final Office Action for U.S. Appl. No. 12/332,904 dated Jan. 3, 2013, 6 pgs. |
Final Office Action for U.S. Appl. No. 12/622,351 dated Jun. 10, 2011, 12 pgs. |
Applicant Initiated Interview Summary for U.S. Appl. No. 12/622,351 dated Nov. 10, 2011, 5 pgs. |
Office Action for U.S. Appl. No. 12/622,351 dated Dec. 1 , 2011, 16 pgs. |
Interview Summary for U.S. Appl. No. 12/622,351 dated Jan. 24, 2012, 2pgs. |
Amendment and Response for U.S. Appl. No. 12/622,351 dated Apr. 17, 2012, 11 pgs. |
Office Action for U.S. Appl. No. 12/622,351 dated Jun. 27, 2012, 26 pgs. |
Applicant Initiated Interview Request Form for U.S. Appl. No. 12/622,351 filed Nov. 2, 2012, 1 pg. |
Applicant Initiated Interview Summary for U.S. Appl. No. 12/622,351 dated Nov. 8, 2012, 4 pgs. |
Office Action Appendix for U.S. Appl. No. 12/622,351 dated Nov. 8, 2012, 3 pgs. |
Amendment and response for U.S. Appl. No. 12/622,351 dated Dec. 26, 2012, 10 pgs. |
Number | Date | Country | |
---|---|---|---|
20090306763 A1 | Dec 2009 | US |
Number | Date | Country | |
---|---|---|---|
61016753 | Dec 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12332904 | Dec 2008 | US |
Child | 12472082 | US |